Ananda Pharma Plc (AQSE:ANA, OTCQB:ANANF) has registered its lead clinical trial for a cannabidiol-based medicine on the US government’s trials database, a key step as the company prepares to begin human testing.
The London-based biopharmaceutical company, which is developing pharmaceutical-grade cannabidiol (CBD) treatments for chronic inflammatory pain, said on Tuesday that its phase I study had been posted to ClinicalTrials.gov under reference NCT06854783.
The study relates to MRX1, Ananda’s lead investigational drug. The candidate is based on high-purity CBD manufactured to European Union Good Manufacturing Practice standards, a regulatory framework that ensures medicines are made consistently and meet stringent quality benchmarks.
Listing the trial is a formal requirement ahead of starting patient enrolment. It ensures that key details about the trial’s aims, structure and eligibility criteria are publicly accessible and compliant with international standards for transparency and research ethics.
Ananda said the results from the study, which will examine how MRX1 is absorbed and processed in the body, will feed into the broader development of its drug pipeline.
The data will be used to support regulatory filings in markets such as the United States and may also form the basis for future academic publications.
The move marks a further step in Ananda’s efforts to build a pipeline of approved cannabinoid-based medicines for conditions that are often difficult to treat with existing therapies.
CEO Melissa Sturgess told investors: "The behind-the-scenes work is now starting to show in the public arena and demonstrates our commitment to the development of regulatory-approved CBD medicines which are available to everyone who needs them, not just those who can afford them."